Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, great list there. Most recent to that list is Adrian Peterson and Robert Griffin III. Nice to see we have the top Sports Dr in the Country on our advisory board!
SVFC$$
A quote from Dr. James Andrews:
“I am dramatically impressed with IntelliCell’s proprietary non-enzymatic method for manufacturing Stromal Vascular Fraction from a person’s own adipose tissue,” said Dr. Andrews. “The amount of SVF cells that this process creates will enable physicians to treat sports injuries without the need for culturing the cells or adding enzymes. We are looking forward to employing this process at our own Institute and to conduct further research with the IntelliCell team on this exciting regenerative medicine.”
http://www.businesswire.com/news/home/20120109006237/en/CORRECTING-REPLACING-IntelliCell-Biosciences-Announces-Addition-World
Human Body's Fat Seen As best Source of Stem Cells For Regenerative Therapies
The human body’s usually unwanted fat tissue may end up, after all, as a very useful contributor to regenerative medicine, a rapidly expanding set of innovative medical technologies that restore human function by enabling the body to repair, replace, or regenerate damaged, aging or diseased cells, tissues, and organs. The use of autologous or one’s own fat, which in itself contains large amounts of various types of stem cells, is a new frontier in medicine that’s widely accepted in Europe and Asia.
Several young biotech firms are already using an adult’s own stem cells not for cosmetic effects alone but to meet the rising demand for anti-aging and rejuvenation treatments, as well as addressing more serious medical conditions, including acute cardiovascular disease, chronic fatigue syndrome, inflammation, arthritis, and hypertension.
Certainly the cell therapy industry is showing great potential for huge growth. “We note that the current business fundamentals in cosmetic and reconstructive surgery are improving,” says Jason Napolitano, analyst at Zacks Investment Research. The leader in the group is Cytori Therapeutics (CYTX), which develops and makes medical products and devices for regenerative medicine.
A smaller biotech firm, IntelliCell Biosciences (SVFC), is a new entry in the game but has made a technological breakthrough in manufacturing “stromal vascular fraction” (SVF) cells derived from a body’s fat that can be used to treat ailments or rejuvenate diseased or damaged tissue and cell function. Under the FDA’s Rule 361, IntelliCells is authorized to commercially sell its SVF stem cells in the U.S. IntelliCell has applied for a patent on the use of ultrasonic cavitaton to break up fat tissue to dramatically increase the yield of SVF cells from just 2 oz. of fat.
Cytori has an array of products, including a device called Celution, which processes a patient’s adipose-derived stem and regenerative cells, for use in cosmetic and reconstructive surgery. Cytori markets a $100,000 machine to physicians to process 6 oz. of fat that in two hours derives about 50 million SVF cells. The machine breaks up the fat cells through a chemical enzyme. Cytori has also developed a Celution system, which has completed two clinical trials, for applications in cardiovascular disease, wound healing, gastronomical intestinal disorders and urinary incontinence.
“We continue to be positive on Cytori,” says Napolitano, as it is nearing that “inflection point” in the business where the clinical data and new product offerings are starting to show up in the revenue line. The upside to its story, he says, comes as the company transitions from the current cosmetic-and-reconstructive surgery approach to regenerative medicine specifically in the area of both acute and chronic cardiovascular disease.
In the case of IntelliCell, the company focuses more on producing large amounts of SVF cells from just a small amount of autologous fat cells of about 2 oz. IntelliCell CEO Dr. Steven Victor found a method that allows the use of ultrasonic cavitation to increase the yield of SVF cells. By using the ultrasonic method, Dr. Victor says he turns the 2 oz. of fat into SVF stem cells of between 0.5 billion and 1.4 billion. The process takes just about 30 minutes at IntelliCell’s labs. Doctors then use the SVF cells for treatment of various ailments, from regenerative cosmetic procedures to repairing tissues involving damaged knees, back injuries, migraine headaches, and multiple sclerosis.
“It is very apparent that a person’s fat cells are the best source of stem cells, which are stored inactively in one’s fat tissues, for use in the fast growing field of regenerative medicine,” says Dr. Victor, a practicing dermatologist for more than 20 years. He says IntelliCell’s proprietary process makes the most cells from the least amount of fat more efficiently and less expensive than any other competing products.
A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori.
A GAME CHANGER IN REGENERATIVE MEDICINE
Says Dr. Victor: “We feel our technology is a game changer in the field of regenerative medicine and that SVF cells show incredible promise for a wide range of clinical uses.”
Awesome is all I can say about the far reaching success of SVFC
Couple of websites I found interesting to read on ReGen Medical (Intellicell is broadly used here).
http://www.regenmedicalpc.com/
http://www.victordermatologyandrejuvenation.com/your-stem-cells-and-regenerative-medicine/
Featured News:
The medical staff at ReGen Medical is pleased to announce that they will be using the patented IntelliCell autologous (your own) cells for a number of promising medical treatments.
Waiting on a IND (Investigational New Drug) as well in addition to Patent.
IntelliCell BioSciences has completed the preclinical protocols in anticipation of beginning a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013. The company provides product today to ReGen Medical, and in doing so is building fantastic database of patient experience that will be used to focus on clinical applications.
Posted June 20th (Re-Post)
Well looky here, Dr. Andrews (The best Sports Dr.) is already on SVFC board. I'll keep digging....
http://www.businesswire.com/news/home/20111221005830/en/IntelliCell-BioSciences-Announces-James-R.-Andrews-M.D.
Dr. Andrews:
Wonder why he is on SVFC advisory board?
Stem Cells are the future:
http://www.stack.com/2013/02/05/rgiii-knee-injury/
http://bleacherreport.com/articles/1451061-adrian-petersons-acl-tear-a-closer-look-at-his-injury-and-incredible-recovery
http://www.theandrewsinstitute.com/News/Featured/Article.aspx?id=800806772
I never knew that SVFC was in Sports Injury until I started investigating! Does everyone know how big this could be? People will be asking how they're sports hero recovered so quickly, and when they find out hopefully they will invest.
Gotta go to work now so good luck today!
http://investorstemcell.com/forum/intellicell-biosciences-inc/13928.htm
Dr. Hackel compared the IntelliCell SVF technology to several other methods of regenerative medicine being considered to be used by the leading orthopedic sports medicine doctors. Dr. Steven Victor, CEO of IntelliCell stated, “We are extremely excited that IntelliCell’s technology compares very favorably to all the other technologies, for procedures common to all major sports industries. We are extremely grateful to have the opportunity to present to over 200 leading doctors and trainers looking to treat major league, collegiate and amateur baseball players with regenerative medicine. IntelliCell Biosciences believes that its technology will be utilized by such experts this year.”
About IntelliCell BioSciences, Inc.
And a whopping 12.5% royalty. This will be huge.
Hey Boiler Room,
Thanks for the PM. I think SVFC will be talked about for a while by a lot of folks. When I started digging up information on this company as the Patent came out I was truly impressed with not only the float but the fundamentals of this company. I realized that the reach of this company is broad. I mean talking about relationships with Merck, the Board, the Medical advisory board, the royalties they will receive from their patents is astounding and very under priced. This will be exciting times to the believers.I will keep digging up DD and post when I get free time.
GLTY and all SVFC shareholders
Don't give up the info to them. I also received an email from Nick and he does not lie. All he says he is working on and he has a firm handle on what's truly going on with the air shares. I don't post much recently because the same ole misleading posts by the same old folks gets old. Good luck OMH
Nice day everyone, looking good for the rest of the week with small float.
GLTY
Nice Job compiling all of the DD. This hopefully will be the sticky!
Good Luck today all,
Good job Nadendla! You can't say there is no DD on SVFC...lol
Can't wait for Monday.
Have a good rest of the weekend all
Even involved in the Dentistry field
Stem cells aid in treating gingival recession
Adding stromal vascular fraction (SVF) containing adipose-derived adult stem cells to existing tissue-regeneration therapies appears to enhance the treatment of gingival recession.
The single-center study, which included seven female patients and one male patient ranging from 23 to 45 years of age with gingival recession, showed that combining a collagen matrix with proprietary SVF adipose processing techniques developed by IntelliCell Bioscience may be a viable alternative to treating gingival recession. In addition, it may eliminate the need for invasive harvesting of periodontal tissue, according to the study authors.
By the end of the six-month prospective study, conducted by private practitioners in New York and Texas, the mean increase in root coverage was 87% for the patients treated. In addition, 66% of treated patients achieved 100% root coverage. These numbers indicate that gingival recession was reversed, with gingival tissue growing back over the root area without having to transplant tissue from another part of the mouth into the gumline, the researchers noted. Post-treatment, patients reported little or no pain and swelling.
Gingival recession is a significant issue in dentistry, and IntelliCell is offering a noninvasive treatment that minimizes patient discomfort and improves outcomes, noted Steven Victor, IntelliCell chairman and CEO, in a press release.
The Wave of Future Medicine
Today's stem cell research offers potential treatment for the future for a wide range of degenerative disorders such as diabetes mellitus, arthritis, Parkinson's disease, Alzheimer's disease, and aging in itself. The most commonly studied and used method - autologous adult stem cell therapy - involves the use of bone marrow, blood, skin, and most recently, fat.
Human Body's Fat Seen As best Source of Stem Cells For Regenerative Therapies
The human bodys usually unwanted fat tissue may end up, after all, as a very useful contributor to regenerative medicine, a rapidly expanding set of innovative medical technologies that restore human function by enabling the body to repair, replace, or regenerate damaged, aging or diseased cells, tissues, and organs. The use of autologous or ones own fat, which in itself contains large amounts of various types of stem cells, is a new frontier in medicine thats widely accepted in Europe and Asia.
Several young biotech firms are already using an adults own stem cells not for cosmetic effects alone but to meet the rising demand for anti-aging and rejuvenation treatments, as well as addressing more serious medical conditions, including acute cardiovascular disease, chronic fatigue syndrome, inflammation, arthritis, and hypertension.
Certainly the cell therapy industry is showing great potential for huge growth.We note that the current business fundamentals in cosmetic and reconstructive surgery are improving, says Jason Napolitano, analyst at Zacks Investment Research. The leader in the group is Cytori Therapeutics (CYTX), which develops and makes medical products and devices for regenerative medicine.
A smaller biotech firm, IntelliCell Biosciences (SVFC), is a new entry in the game but has made a technological breakthrough in manufacturing stromal vascular fraction (SVF) cells derived from a bodys fat that can be used to treat ailments or rejuvenate diseased or damaged tissue and cell function. Under the FDAs Rule 361, IntelliCells is authorized to commercially sell its SVF stem cells in the U.S. IntelliCell has applied for a patent on the use of ultrasonic cavitaton to break up fat tissue to dramatically increase the yield of SVF cells from just 2 oz. of fat.
In the case of IntelliCell, the company focuses more on producing large amounts of SVF cells from just a small amount of autologous fat cells of about 2 oz. IntelliCell CEO Dr. Steven Victor found a method that allows the use of ultrasonic cavitation to increase the yield of SVF cells. By using the ultrasonic method, Dr. Victor says he turns the 2 oz. of fat into SVF stem cells of between 0.5 billion and 1.4 billion. The process takes just about 30 minutes at IntelliCells labs. Doctors then use the SVF cells for treatment of various ailments, from regenerative cosmetic procedures to repairing tissues involving damaged knees, back injuries, migraine headaches, and multiple sclerosis.
A GAME CHANGER IN REGENERATIVE MEDICINE
Says Dr. Victor: We feel our technology is a game changer in the field of regenerative medicine and that SVF cells show incredible promise for a wide range of clinical uses.
Walter Schenker, president of MAZ Capital Advisors, who owns IntelliCell shares, said his wife and daughter underwent treatment at the IntelliCell lab for knee ailments, which proved successful. IntelliCell has an exciting technology that uses ones own fat tissues for the incredible treatment or repair of damaged tissues, says Schenker.
Dr. Victor says IntelliCells labs have treated more than 100 patients this year which all produced successful results. One such patient, Denise Aversano, underwent treatment at one of IntelliCells labs for severe and chronic back ailment which had been a source of incessant pain. Prior to the IntelliCell procedure, she had been in physical therapy for years, with no success of alleviating her misery.
Three days after her treatment at IntelliCell on April 22, the pain started to dissipate and eventually went away, to her surprise. Denise said she was able to roll out of bed in the morning for the first time in years. Shopping had always been difficult for her because of her constantly aching back. But after the surgery, she was able to go to the mall to shop for the first time in many years, without pain. I was able to enjoy shoping again and was able to pick up packages and carry them to my car with no help from anybody, she said.
So who is Dr. Zain Khapley exactly?
Well in March 2013 Heart Surgeon Zain Khalpey Appointed to Lead Heart Transplant Program & Mechanical Circulatory Support Surgery Program at UAMC.
Dr. Khalpey is engaged in ex vivo reconditioning of marginal human hearts and lungs, which will generate functional lung and heart tissue that ultimately can be used for transplantation. This reconditioning process uses human cadaveric lungs that are decellularized (chemically stripped of its cells, leaving behind the extracellular tissue and lung scaffolds). That structure is “re-seeded” with autologous stem cells to rebuild the organ.
He also is involved in creating clinical “bridge-to-regeneration” trials, in which autologous stem cells (SVFC comes into play) will be injected into failing hearts with the hope of recovery in an era of limited hearts for transplantation.
What has Dr. Khapley been working on since March?
Jun 17, 2013 (ACCESSWIRE via COMTEX) -- NEW YORK, NY June 17, 2013 / -- IntelliCell BioSciences, Inc. ("Company") (otc pink:SVFC) announced today that Dr Zain Khalpey, MD, PhD, MRCS (Eng) Director, Heart Transplant Program & Mechanical Circulatory Support, Division of Cardiothoracic Surgery?Associate Professor of Surgery, Physiological Sciences & Biomedical Engineering, University of Arizona College of Medicine has joined the Advisory Board.
Dr. Khapley has brought all of his knowledge to Intellicell to sit on our Board of Directors.
This is huge!!! Can't wait for developments at SVFC.
27 million shares confirmed in the float. Very low.......
From Cjstockup:
There are 500M authorized shares and the outstanding shares after full dilution is upwards of 150M with 39M in warrants
Who is helping SVFC get through clinical trials?
http://www.numoda.com/pages/media.html
Numoda also is working with Advaxis
IntelliCell BioSciences, Inc Announces Powerful Collaboration with Numoda Corporation
New Partnership Created to achieve Faster, More Cost Effective Regenerative Medicine Research
IntelliCell’s Breakthrough Manufacturing Technology to Dramatically Lower Cost of Producing Autologous Stem Cells without Expansion
Numoda Capital Innovations to Invest in IntelliCell
NEW YORK--(BUSINESS WIRE)--IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today that it has signed an agreement with Philadelphia based Numoda Capital Innovations, an investment arm of Numoda Corporation, pursuant to which Numoda Capital has agreed to become an investor in the Company which will be aimed at bringing faster, more cost effective clinical trials to the university level.
“incredible research in stem cells is being done in at least 55 universities; this unique collaboration allows these research facilities to further their own pursuits through access to these exciting technologies.”
This collaboration would combine the innovative patented platforms and reporting engines of Numoda with the cutting edge proprietary technologies utilized by IntelliCell in separation of adipose tissue into stromal vascular fraction containing stem cells, to bring the advantage of these technologies to further promote vital university clinical development.
Presently, autologous stem cell research is focused on deriving these cells from bone marrow or adipose tissue. In the case of bone marrow, the cells need to be cultured to increase the number of cells to therapeutic numbers. This takes weeks to accomplish and is costly. With enzymatic separation, the enzymes are costly (over $1,000 per sample) and their use is controversial. Prior to the introduction of the proprietary, non-enzymatic extraction process utilized by IntelliCell, adipose derived stem cells were produced using enzymes to yield the stromal vascular fraction (SVF cells) that resides in the adipose tissue. Using either method, stem cell research is extremely costly and time consuming. IntelliCell’s non-enzymatic process allows a patient to be treated from start to finish in less than one hour. Dr. Steven Victor said “using only 60cc’s versus 200cc’s of adipose tissue that is required for the enzymatic process, in about 30 minutes, IntelliCell is able to generate between 0.5 billion and 1 billion SVF cells. A majority of the SVF cells are all the lineages of multipotent stem cells that exist in our body. Only sound and saline are used to manufacture what we believe to be the largest amount of autologous, stem cells produced in the shortest amount of time, and at 10-20% of the research costs required when using traditional enzymatic methods. This will dramatically increase the efficiency of the R&D dollars spent by any stem cell research center. We are extremely excited to be collaborating with Numoda Corporation to combine our breakthrough technology with their IT technology. Together major universities conducting stem cell research will be able to perform many more trials for the same amount of money.”
I would love to know if Dr. Andrews injected Robert Griffin III or Superman Adrian Peterson with SVFC cells? I would try and contact him but he already said no comment on type of cells in an ESPN article.
Small float, once traded on Nasdaq this will be large again. The news just has to be released out somehow...
GLTA
Did anyone see this? A new IND in mid 2013
IntelliCell BioSciences has completed the preclinical protocols in anticipation of beginning a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013. The company provides product today to ReGen Medical, and in doing so is building fantastic database of patient experience that will be used to focus on clinical applications.
A lot of strong DD out there on Intellicell Biosciences (SVFC)
I am still excited about having Dr. James Andrews (Sports Surgeon) on our board. He believes regenerative medicines are the future and resides on SVFC's BOD
http://www.allmedicaltourism.com/Pages/Directory/intellicell9November2011.htm
Please take a look at all of the current locations for tissue processing centers:
http://ir.issuerdirect.com/template_files/svfc/investor-relations.html
Company Description
Contact Info
460 Park Avenue
17th Floor
New York, NY 10022
United States
Phone: 646-576-8700
Fax:
www.intellicellbiosciences.com
Intellicell Biosciences, Inc., a regenerative medicine company, focuses on developing and commercializing regenerative medical technologies in markets with unmet clinical needs. The company’s IntelliCells is potential to treat aesthetic conditions, orthopedic and sports injuries, and pain, and also clinical conditions involving cardiac, gastrointestinal, periodontal, and autistic disorders. The company has the licensing agreements covering the territories of Canada, Australia, New Zealand, and Thailand. The company has developed proprietary technologies that allow for the reproducible separation of stromal vascular fraction (branded IntelliCell) containing adipose stem cells that can be performed in tissue processing centers and in doctors’ offices. The company focuses on the expanding regenerative medical markets using a proprietary, patent pending process to separate adult autologous vascular cells (AAVC’s) from blood vessels in adult adipose (fat) tissue. These AAVC’s, which are also referred to as stromal vascular fraction (SVFs), are a heterogeneous mixture of regenerative cells and autologous adult stem cells that promote the healing of injured tissue. Strategy The company plans to focus its initial efforts on regenerative medicine in the areas of Aesthetics, Orthopedics, Sports Medicine, Pain Management and Periodontal Diseases. The company intends to engage in a multi-pronged approach with respect to the utilization and commercialization of its proprietary process that would involve entering into technology licensing agreements and related service agreements with physicians, physician practice groups, hospitals and ambulatory service centers located in the United States. Significant Events In 2011, the company entered into a lab services agreement with Regenastem, Inc., a Canadian corporation, pursuant to which it granted the licensee the right and license to utilize its proprietary process as well as its trademarks for the purpose of providing tissue processing services for humans and animals in Canada. In 2011, the company entered into a lab services agreement with Cell-Innovations Pty Ltd. pursuant to which it granted the licensee the right and licenses its proprietary process and trademarks for the purpose of providing tissue processing services for humans in Australia and New Zealand. In April 2012, the company entered into a lab services license agreement with StemCells 21 Co., Ltd. pursuant to which it granted the licensee, a non-assignable, non-transferable, license to utilize and commercially exploit its proprietary process and trademarks, solely for the provision of the separation of Adipose Stromal Vascular Fraction from fat tissue within the Kingdom of Thailand. The company has licensing agreements covering the areas of Philadelphia, Pennsylvania, Dallas/Ft. Worth, Texas, Palm Beach, Florida, Metaire, Lousiana, Lake Mary, Florida, Denver, Colorado,Sugarland, Texas and Baton Rouge, Louisiana. The company has entered into the licensing agreements covering the areas of Philadelphia, Pennsylvania; Dallas/Ft. Worth, Texas; Palm Beach, Florida; Metaire, Louisiana; Lake Mary, Florida; Denver, Colorado; Sugarland, Texas; and Baton Rouge, Louisiana. It has licensing agreements with Thomas E. Young MD, LLC; Foursight LLC; Dauterive Medical, Inc.; AGE Management LLC; AllWin Scientific Corporation; PBH Holdings, LLC; and Regenerative Laboratory Services of Baton Rouge, LLC. In May 2012, IntelliCell BioSciences, Inc. announced that it has entered a sponsored research agreement with the Institute for Cell Engineering and Regenerative Medicine (ICERM) at the University of Florida. In April 2012, the company entered into a technology license and administrative services agreement with Regen Medical P.C. Pursuant to the agreement, it granted Regen Medical the license to utilize its proprietary process and technology for its patients. In June 2012, IntelliCell BioSciences, Inc. announced that it has opened its new Tissue Processing Laboratory medical facility at 460 Park Avenue, 17th floor, New York, New York, in conjunction with the ReGen Medical, PC medical practice. As a measure of its commitment to be compliant with the FDA, IntelliCell is engaged with biologics and legal experts to assist the company with compliance issues related to applicable federal and state regulations. In November 2012, IntelliCell BioSciences, Inc. announced that it has entered a sponsored research agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey. History Intellicell Biosciences, Inc. was founded in 2010.
So many options for SVFC and it's newly patented product.
On the other hand, the autologous model, like IntelliCell BioSciences Inc.'s (SVFC:OTCPK) adipose sonifcation process (cells are separated using sonic energy), could be very attractive for cardiac patients with CMI. If we think of the lowest of the low-hanging fruit, we think of anybody undergoing a tummy tuck. What is happening to that fat now? It's being thrown away. Imagine if that was reintroduced into your body for rejuvenation. Now the person getting liposuction is a candidate for stem cell therapy. Many physicians are actually doing this today under minimally manipulated and homologous guidelines. The area is in dispute and represents a gray area in terms of FDA regulations.
I can see a day when stem cells from these procedures are cryopreserved. Down the road, should you break your arm or your ankle, those cells could be used to help you heal rapidly. I think Cytori's device has enormous potential. I respect the fact that it is targeting CMI with a peak oxygen consumption endpoint along a PMA (device) pathway.
Once the company completes the current phase 2 study successfully, all it will need to do is one modestly sized phase 3 trial. Proving safety is less of an issue with the device pathway, so the pivotal trial's focus is a p-value (statistically valid result) on a relevant endpoint.
TLSR: Do you have one or two ideas to close with?
JK: I'd like to talk about IntelliCell BioSciences—and I know this will be controversial, only because its CEO, Dr. Steven Victor, is also the founder of ReGen Medical. ReGen Medical is a state-of-the-art hospital in midtown Manhattan that provides stromal vascular fraction cellular therapy, which contains stem cells, to patients today. The hospital is a beautiful, brand-new facility that treats high-end patients.
The therapy is provided to patients through physicians (orthopedists, urologists, plastic surgeons, etc.) that have practicing rights at ReGen Medical. The clinicians are allowed to put a patient's own cells back into his or her own body, provided the cells are not manipulated, processed or expanded. This is in accordance with the FDA's "minimal manipulation and homologous use" rule.
The IntelliCell process, branded IntelliSonics, is similar to the Cytori process in that they both use lipoaspirate. But the IntelliCell process produces a different cellular population because, with its sonification (ultrasound) process, the blood components are not washed out. The stromal vascular fraction of IntelliCell contains the hematopoietic cells. The final product is quality-controlled, checked for any contamination and cell viability is measured.
IntelliCell BioSciences has completed the preclinical protocols in anticipation of beginning a clinical trial for osteoarthritis of the knee under an FDA investigational new drug application in mid-2013. The company provides product today to ReGen Medical, and in doing so is building fantastic database of patient experience that will be used to focus on clinical applications.
AWESOME!!!! BJames15 you have a way to calm us longs : )
I never knew that SVFC was in Sports Injury until I started investigating! Does everyone know how big this could be? People will be asking how they're sports hero recovered so quickly, and when they find out hopefully they will invest.
Gotta go to work now so good luck today!
http://investorstemcell.com/forum/intellicell-biosciences-inc/13928.htm
Dr. Hackel compared the IntelliCell SVF technology to several other methods of regenerative medicine being considered to be used by the leading orthopedic sports medicine doctors. Dr. Steven Victor, CEO of IntelliCell stated, “We are extremely excited that IntelliCell’s technology compares very favorably to all the other technologies, for procedures common to all major sports industries. We are extremely grateful to have the opportunity to present to over 200 leading doctors and trainers looking to treat major league, collegiate and amateur baseball players with regenerative medicine. IntelliCell Biosciences believes that its technology will be utilized by such experts this year.”
About IntelliCell BioSciences, Inc.
http://www.bafitis.com/stem_cell_therapy_bafitis.asp
WHAT CONDITIONS HAVE BEEN TREATED BY ADIPOSE-DERIVED STEM CELLS?
The United States has been slightly behind in the clinical use of stem cells, but veterinarians have been using equine stem cells derived from fat to correct aging or damaged tendons in horses for over seven years with amazing results! In humans, stem cells have been utilized as follows in the United States:
a. Dermal injections for dermal regeneration with improved lines and wrinkles.
b. Dermal injections for acne scars.
c. Dermal injections for burns and ulcerated wounds.
d. Addition of stem cells to harvested fat for greater take, regeneration, and volumizing of the face and body.
e. These cells have also been successfully utilized in the knee, elbow, and hands in terms of injections for arthritis.
f. Knee injections for cartilage repair or improvement for cartilage loss/ damage.
There are physicians who have also utilized stem cells via IV drip for osteoarthritis and improvement in pain from inoperable joint/spine disease.
Dr. Andrews:
Wonder why he is on SVFC advisory board?
Stem Cells are the future:
http://www.stack.com/2013/02/05/rgiii-knee-injury/
http://bleacherreport.com/articles/1451061-adrian-petersons-acl-tear-a-closer-look-at-his-injury-and-incredible-recovery
http://www.theandrewsinstitute.com/News/Featured/Article.aspx?id=800806772
Well looky here, Dr. Andrews (The best Sports Dr.) is already on SVFC board. I'll keep digging....
http://www.businesswire.com/news/home/20111221005830/en/IntelliCell-BioSciences-Announces-James-R.-Andrews-M.D.
Extracting autologous stem cells from fat will be the first stem cell market and big pharma will want a piece. All major sports teams are currently lining up and will likely be the first clients.
IntelliCell BioSciences (SVFC) at the American Sports Medicine Institute Held in Conjunction with and at the Andrews Sports Medicine & Orthopedic Center in Birmingham, AL
Anybody ever hear of the famous Dr. James Andrews? Know for reapiring ACL/PCL/MCL tears in Major Sports Stars. Recently he reapired Adrian Peterson (Minnesota Vikings)knee so well and quick he went on to capture the rushing title in the NFL last year in only 7-9 months which is insanely fast.
Most recently just did surgery on Robert Griffin III (Washington Redskins QB). Reports that he will start the season after 7-8 month recovery which usually can take up to 2 years.
Would be great to get this exposure since SVFC was at the sports complex!!!!
http://www.biospace.com/News/intellicell-biosciences-at-the-american-sports/248615
Treating Diabetic for critical limbs currently in Clinical studies:
NEW YORK, Sept. 13, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC) announced today that it will be initiating a groundbreaking in-human clinical study to treat people who suffer from diabetic induced critical limb ischemia wounds. IntelliCell has developed a proprietary treatment methodology using its autologous (your own) cellular therapy that includes adult stem cells that have demonstrated regenerative capabilities in anecdotal studies of patients treated. According to the American Diabetes Association, there are "over 65,000 lower limb amputations performed in the United States" as a direct consequence of diabetes and hundreds of thousands of diabetes related amputations globally.
Dr. Steven Victor, Chairman and CEO of IntelliCell stated, "Diabetes is a growing problem in the United States and around the world. We hope to show that our unique autologous cellular therapy may make a contribution to those who suffer from this terrible disease and reduce the number of people that undergo amputations from non-healing wounds in their legs and other extremities."
IntelliCell BioSciences
www.intellicellbiosciences.com
Intellicell™ Biosciences, Inc. is an emerging leader in regenerative medicine using adipose (fat) derived stromal vascular fraction containing adult stem cells. To date, the Company has developed proprietary technologies that allows for the efficient and reproducible separation of stromal vascular fraction (branded "IntelliCell™") containing adipose stem cells that can be performed in tissue processing centers and in doctor's offices. The Company is also engaged in clinical studies at major medical centers to obtain FDA approval for clinical indications for their IntelliCells.
http://www.proactiveinvestors.com/companies/news/16309/intellicells-stem-cell-technology-validated-by-merck-study-16309.html
Patent
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22intellicell+biosciences%22.ASNM.&OS=AN/
Licensing their Patents for upfront payment and 12.5% royalties. This is a great way to keep revenue coming in.
http://www.wnd.com/markets/news/read/20356239/intellicell_biosciences_announces_the_licensing_of_its_proprietary_patent
IntelliCell's fat-derived stem cells termed "technological breakthrough" in Forbes
29th Aug 2011, 3:09 pm by Olivia D'Orazio
IntelliCell BioSciences (OTCBB:SVFC) has made a technological breakthrough into the regenerative medicine field, according to blog entry in Forbes.
The company, through its proprietary technology, processes stromal vascular fraction (SVF) stem cells, derived from one's own body fat.
Fat stem cells are now the cutting edge, with many doctors and companies researching the use of them for anti-aging effects, as well as for the treatment of more serious conditions like arthritis, congestive heart failure, gum recession, and wound healing.
IntelliCell's SVF cells can be used to treat certain conditions, or rejuvinate damaged tissue and cell function. The company, which under the FDA is authorized to commercially sell its SVF cells, has also applied for a patent on its use of ultrasonic cavitations to break up fat cells, which increases the number of SVF stem cells that can be extracted from just two ounces of fat to between 500 million and 1.4 billion, Forbes said.
The company's technique takes approximately 30 minutes, costs less than other stem cell extraction products, and the stem cells can be returned to a patient’s doctor in the same day.
"It is very apparent that a person’s fat cells are the best source of stem cells, which are stored inactively in one’s fat tissues, for use in the fast growing field of regenerative medicine," IntelliCell CEO, Dr. Steven Victor told Forbes.
Forbes noted that IntelliCell's technology can produce an average of 10 times the number of stem cell-containing SVF cells as traditional methods, which require the use of enzymes, according to a study of the company's technology by a unit of Merck AG.
Indeed, these fat stem cells have similar potential to embryonic stem cells in their pluripotency, and are from a source that involves no moral or ethical issues, as well as no chemical additives required for digestion of the tissue.
In the aesthetic world, the use of autologous adipose, or fat, stem cells has become widely accepted in Europe and Asia. Since the US FDA published its laws on autologous stem cells in mid-2009, the field has expanded rapidly.
IntelliCell has also treated more than 100 patients this year alone, Forbes said, including the wife and daughter of MAZ Capital Advisors' president, and IntelliCell shareholder, Walter Schenker. Each underwent a successful treatment at an IntelliCell lab for knee ailments, Forbes cited.
IntelliCell adds five new members to its medical advisory board
9th Jan 2012, 4:05 pm by Brad Lemaire
IntelliCell Biosciences (OTC:SVFC.PK) Monday announced the addition of five orthopaedic surgeons and sports medicine doctors to its medical advisory board to bring its proprietary non-enzymatic process for the production of fat tissue to market.
The new additions to the board are poised to alter the way sports injuries are treated, the company said.
The notable advisory board additions include: James Andrews, Joshua Hackel, Jeffrey R. Dugas, Kevin Wilk, of the Andrews orthopaedic and sports medicine and as well as Frederic Nicola from the sports and spine centre.
By partnering with prestigious sports medicine doctors, IntelliCell executives believe that IntelliCell’s SVF cell therapy will benefit professional athletes in the rehabilitation and prevention of sports injuries, thus elongating players’ careers.
IntelliCell has developed an in-house technology where it can process stromal vascular fraction cells that contain high concentrations of adipose stem cells.
The company believes that it is currently the only one that does not use enzymes in processing adipose tissue, and actually counts and checks the adipose stem cells they manufacture.
The company believes the market for non-enzymatic stromal vascular therapy for the professional sports medicine market is in excess of $1 billion.
In the aesthetic world, the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the US FDA published its laws on autologous stem cells in mid-2009, the field has expanded rapidly.
IntelliCell has established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach.
Sorry, this is not old,but relevant information for funding trials. Please do some DD. BMSN will use this for upcoming clinical trials
Don't forget they had to raise capital for the MIN Gene Silencing rights thus some dilution
Don't forget they had to raise capital for the MIN Gene Silencing rights thus some dilution
The infrastructure and the board is awesome! I can't wait with this cast.
BMSN has secured 20,000,000 in funding from Southridge.
Hi all Longs! I am in this baby.
I am excited to buy in to this one and add.
Just take a look at some facts shall we? They are staffing with top notch Doctors and research firms, receiving patents,small float, did I mention really small float? Once it takes hold it will be back on Nasdaq. Set it and forget it, come back at retirement or in a year. Not too many pennies out there with this potential.
All links below did not just go away, they have been working on this stuff and it's all going to come together.
Patents...
http://www.biospace.com/News/intellicell-biosciences-receives-us-patent-for-its/299997
http://finance.yahoo.com/news/intellicell-biosciences-announces-cellular-tissue-164000628.html
Adding Key Dr.s, advisory board and resources: Looks like a ramping up phase to me....
Dr. Fisch is joining our Advisory Board and will be the Director of Urology for IntelliCell. He is a pioneering surgeon and respected on the national stage for his work on microsurgical techniques.
http://www.biospace.com/News/intellicell-biosciences-announces-the-addition-of/281901
Mr. Hershman has long been recognized as one of the most influential business people worldwide and we are looking forward to working with him as we strengthen the IntelliCell executive management team with world class people."
http://www.biospace.com/News/intellicell-biosciences-announces-michael-hershman/280531
Mr. Holubiak is an accomplished biotech and pharmaceutical senior executive with over 30 years of industry experience including directing Roche Laboratories, a $2.8 billion dollar company with over 3,500 employees, as its President. Mr. Holubiak also serves as Director for Ventrus BioSciences, Inc. and Chairman of the Board for BioScrip, Inc.
http://www.biospace.com/News/intellicell-biosciences-announces-myron-z-holubiak/277618
"Dr. Caplan's expertise in regenerative medicine is acknowledged in our entire industry and we are very pleased to have him assist our company as it moves forward. Dr. Caplan's unique experience in our industry has helped emerging companies take many products from the laboratory and into successful commercialization.
http://www.biospace.com/News/intellicell-biosciences-announces-dr-arnold-i/263167
Adding Partners:
http://www.biospace.com/News/intellicell-biosciences-announces-research/280929
http://www.biospace.com/News/intellicell-biosciences-announces-collaborative/261348
Can go on and on. May have to weather the naked shorts,shorts, MM's and day to day flippers but the longs will prevail.
IMO and GLTA
How can you discredit this stuff? It's amazing and cutting edge, guess what? We have patent:
IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that it has been successful in manufacturing stromal vascular cells from Non-Living adipose tissue from a deceased tissue donor. These cells have been grown in culture and demonstrated to have the correct CD antibody markers for mesenchymal stem cells and other cells that are consistent with stromal vascular fraction cells.
Dr. Steven Victor, CEO of IntelliCell, stated "We are very pleased to have Mr. Frank join our organization and gain access to his biotechnology expertise and leadership. He has made a tremendous impact on our industry and specifically for the companies he has chosen to be affiliated with. We look forward to his counsel as we strive to achieve new landmarks in regenerative medicine."
Regenerative Medicine is the future:
http://www.cnn.com/2011/OPINION/07/10/atala.grow.kidney/index.html
Regenerative medicine is an emerging field that provides treatments to repair, regenerate, or replace damaged cells and tissue. The applications include therapies for Alzheimers, diabetes, cancer, and spinal injuries.
Stem Cells are the Key to Regenerative Medicine
Much of regenerative medicine research, such as that conducted at the University of California San Francisco, involves the use of stem cells: cells that occur in every multicellular organism that have the potential to differentiate into many types of specialized cells.
http://blog.lef.org/2012/05/regeneration-future-of-medicine.html
Hang in there Longs, we will win the war!
Bought in today because the scanner lit up with volume and $ gainer indicators :)
Looks good for today. Good Luck to you all.
I like the way you think! Good luck to everyone!
BMSN